How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
https://www.zacks.com/stock/news/2259557/how-should-you-play-merck-mrk-stock-ahead-of-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2259557
Apr 22, 2024 - Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
0
Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth
https://www.zacks.com/stock/news/2257704/merck-mrk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2257704
Apr 18, 2024 - Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Merck (MRK) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2257229/merck-mrk-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2257229
Apr 17, 2024 - In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day.
0